... Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist) RET inhibitors Cabozantinib (Cometriq, Cabometyx) Pralsetinib (Gavreto ...
NSCLC Targeted Therapy: 8 Facts
... Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist) RET inhibitors Cabozantinib (Cometriq, Cabometyx) Pralsetinib (Gavreto ...
... target these fusion-related biomarkers.Targeted therapies based on specific gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) RET Fusion Pralsetinib (Gavreto ...
Biomarkers for Lung Cancer: 12 Things To Know
... target these fusion-related biomarkers.Targeted therapies based on specific gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) RET Fusion Pralsetinib (Gavreto ...
... Two targeted therapies, pralsetinib (Gavreto) and selpercatinib (Retevmo), have been developed to block the receptor from sending growth signals. Cabozantinib (Cabometyx, Cometriq) may also be used in some cases.HER2In a small number of NSCLC cases, changes in the HER2 gene help cancer cells grow and divide. ...
How Does Targeted Therapy for Lung Cancer Work?
... Two targeted therapies, pralsetinib (Gavreto) and selpercatinib (Retevmo), have been developed to block the receptor from sending growth signals. Cabozantinib (Cabometyx, Cometriq) may also be used in some cases.HER2In a small number of NSCLC cases, changes in the HER2 gene help cancer cells grow and divide. ...
... ceritinib (Zykadia), crizotinib (Xalkori), and lorlatinib (Lorbrena) ROS1 inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) RET inhibitors, such as pralsetinib (Gavreto ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... ceritinib (Zykadia), crizotinib (Xalkori), and lorlatinib (Lorbrena) ROS1 inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) RET inhibitors, such as pralsetinib (Gavreto ...
... Two inhibitors have been developed to block the function of the RET protein: selpercatinib (Retevmo) and pralsetinib (Gavreto).MET InhibitorsIn some cases of NSCLC, a MET gene mutation produces a protein that encourages tumor cells to spread and grow. Capmatinib (Tabrecta) directly blocks the function of MET proteins. ...
Lung Cancer Treatment Options
... Two inhibitors have been developed to block the function of the RET protein: selpercatinib (Retevmo) and pralsetinib (Gavreto).MET InhibitorsIn some cases of NSCLC, a MET gene mutation produces a protein that encourages tumor cells to spread and grow. Capmatinib (Tabrecta) directly blocks the function of MET proteins. ...
Join
